Quantcast
Last updated on April 16, 2014 at 12:31 EDT

Latest JN-International Medical Corporation Stories

2013-08-08 16:26:39

Vaccine was Safe, Easily Administered and Highly Protective ROCKVILLE, Md., Aug. 8, 2013 /PRNewswire/ -- Results of a phase I clinical trial of the Sanaria(®) PfSPZ Vaccine to combat malaria, published today in the online issue of Science magazine, show that the vaccine provided complete protection against malaria in subjects who were exposed to Plasmodium falciparum parasites. Plasmodium falciparum is the malaria parasite that causes more than 600,000 deaths annually. "While...

2013-06-13 08:25:25

- "Get in the Game" urges parents to take action and vaccinate against meningococcal disease in advance of the upcoming sports season SILVER SPRINGS, Md. and SWIFTWATER, Pa., June 13, 2013 /PRNewswire/ -- Voices of Meningitis, a public health initiative of the National Association of School Nurses (NASN) in collaboration with Sanofi Pasteur, announced today the launch of Get in the Game: Keeping Teens Healthy, a new program to help educate parents on the danger and prevention of...

2012-10-24 15:25:22

In the news release, Pfenex Inc. Awards Althea Technologies a Contract for cGMP Manufacturing of Circumsporozoite Protein from Plasmodium falciparum, a Key Malaria Antigen, issued 24-Oct-2012 by Pfenex Inc. over PR Newswire, we are advised by the company that in the third paragraph, the last sentence should have been a quote attributed to Dr. Annie Mo. This quote is now the fourth paragraph. The complete, corrected release follows: Pfenex Inc. Awards Althea Technologies a Contract for cGMP...

2012-10-24 07:30:36

SAN DIEGO, Oct. 24, 2012 /PRNewswire/ -- Pfenex Inc. today announced that it has awarded Althea Technologies a contract for the current Good Manufacturing Practice (cGMP) manufacturing of circumsporozoite protein (CSP) from Plasmodium falciparum, an important and proven component of an effective malaria vaccine. Althea Technologies will implement the cGMP-ready Pf?nex Expression Technology(TM)-based production process that was developed at Pfenex over the past several months. Processes for...

2012-06-05 11:21:11

A new technique that accurately determines the risk of infants in endemic countries developing clinical malaria could provide a valuable tool for evaluating new malaria prevention strategies and vaccines. The technique could even help to understand how anti-malarial vaccine and treatment strategies act to reduce malaria, say researchers from the Walter and Eliza Hall Institute, Swiss Tropical and Public Health Institute, University of Basel and the Papua New Guinea Institute of Medical...

2011-05-17 11:00:00

SAN DIEGO, May 17, 2011 /PRNewswire/ -- Pfenex Inc.'s Reagent Proteins division announced today that it has submitted a Biologics Master File (BMF) to the United States Food and Drug Administration for its cGMP grade CRM197 carrier protein to support the development of conjugate vaccine products by its partners. Reagent Proteins is supplying cGMP grade CRM197 carrier protein to multiple partners in support of their novel conjugate vaccine development efforts. As part of the product...

2010-04-18 23:01:00

ROCKVILLE, Md., April 19 /PRNewswire/ -- Protein Potential LLC has received support from the National Institute of Allergy and Infectious Diseases (NIAID) of the NIH in the form of a Phase II Small Business Innovation Research (SBIR) Grant. The three-year award totaling approximately $3 million will support translational research to develop a vaccine for the prevention of malaria caused by the parasite Plasmodium vivax. Approximately 40% of the world's population is at risk from malaria...

2008-10-17 03:00:00

Dutch biopharma company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) and the Aeras Global TB Vaccine Foundation today announce the start of a Phase I clinical trial in Kenya of the jointly developed tuberculosis (TB) vaccine candidate, AERAS-402/Crucell Ad35. The announcement is made in the lead up to the 39th Union World Conference on Tuberculosis and Lung Disease in Paris, France (16-20 October, 2008). This first-ever study of the new...